Minovia Therapeutics – Kuwait Financial Express http://www.kuwaitfinancialexpress.com Thu, 05 Jan 2023 13:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member http://www.kuwaitfinancialexpress.com/minovia-therapeutics-appoints-maha-radhakrishnan-chief-medical-officer-at-biogen-as-board-member/ Thu, 05 Jan 2023 13:00:00 +0000 http://www.kuwaitfinancialexpress.com/?p=306639 TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics (Minovia), a clinical–stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.

Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction. As a trained physician, Maha is a senior leader with extensive pharmaceutical and biotech experience covering clinical development, post–marketing regulatory activities, medical affairs, safety, and reimbursement requirements. Maha is the Chief Medical Officer of Biogen, and in her previous roles, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, Senior Vice President and Head of Worldwide Medical at Bioverativ Therapeutics Inc., and Head of Europe & Canada Medical and US Medical at Biogen. She has also worked at Bristol Myers Squibb, Cephalon, and United Health Group before first joining Biogen in early 2013.

Maha has significant experience across a broad range of therapeutic areas and disciplines, including the central nervous system (neurology and psychiatry), rheumatology and immunology, rare blood disorders, ophthalmology, cardiology, diabetes, and internal medicine.

Natalie Yivgi Ohana, Co–Founder and CEO Minovia Therapeutics, said, "Mitochondrial diseases are often fatal and currently viewed as untreatable, something we are working relentlessly to change. So far twelve patients suffering Primary Mitochondrial Diseases were dosed with our Mitochondrial Augmentation Technology, both through compassionate use program and a Phase 1/2 trial in Israel. Minovia Invested greatly in research and development in the last two years, establishing strong scientific and GMP foundations, which will enable us to seek approval for Pearson Syndrome and expand to other disease areas. As board member at Minovia, we will be able to draw on Maha's considerable medical, regulatory and drug development expertise and experience in bringing successful treatments to patients with primary and secondary mitochondrial diseases."

Maha added: "Minovia is changing the way we look at mitochondrial therapies. They are on the precipice of meaningfully and measurably improving the lives of patients in need. I look forward to providing oversight and helping Minovia achieve its goals to approve their novel mitochondrial cell therapies in multiple disease areas."

The appointment of Maha as a board member follows on from Minovia's recent partnership with Astellas Pharma to develop novel Mitochondrial Cell Therapies, as well as the initial data publication in Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.abo3724).

Contact
Info@minoviatx.com

About Minovia Therapeutics
Minovia Therapeutics is a clinical stage company and the first to use a cell therapy approach to treat patients affected with mitochondrial diseases through its Mitochondrial Augmentation Technology (MAT) platform. MAT is being developed as a robust and scalable therapeutic platform targeting the root cause of diseases generated by mitochondrial dysfunction. The lead product, MNV–201 is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments in the United States and the unmet medical need is immense. After completing an IND enabled phase I/II clinical trial in Pearson Syndrome, a fatal pediatric disease, Minovia is planning to accelerate the clinical development for Pearson Syndrome and expand the pipeline to other Hematological/Mitochondrial–related diseases. Harnessing the power of mitochondria, Minovia is committed to exploring the full potential of its proprietary platform to address mitochondrial diseases ranging from orphan indications to more common and age–related diseases.

For more information, please visit"http://minoviatx.com/.


GLOBENEWSWIRE (Distribution ID 8724390)

]]>
Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023 http://www.kuwaitfinancialexpress.com/minovia-therapeutics-to-present-at-biotech-showcase-on-tuesday-january-10-2023/ Tue, 03 Jan 2023 07:00:28 +0000 http://www.kuwaitfinancialexpress.com/?p=306655 WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics, a clinical–stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.

Time: 9:45 AM PST

Track: Franciscan C (Ballroom Level)

Biotech Showcase is an investor conference featuring insights from top investors and biopharma executives.

Interested parties can register to attend the event here:

https://informaconnect.com/biotech–showcase/registration–options/

Additionally, CEO Natalie Yivgi–Ohana and CBO Shai Melcer will be in San Francisco from January 8–12, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.

Individuals interested in meeting with CEO Natalie Yivgi–Ohana and CBO Shai Melcer can contact shai.melcer@minoviatx.com

About Minovia
Minovia Therapeutics is a clinical–stage global biotechnology company committed to the discovery and development of novel approaches to treating diseases caused by mitochondrial dysfunction. Minovia's Mitochondrial Augmentation Technology (MAT) platform is designed to extend and enhance human lives by restoring mitochondrial function using autologous stem cells enriched with healthy, functional mitochondria. This unique approach capitalizes on the natural ability of mitochondria to transfer between cells. The company's initial clinical focus is on primary mitochondrial diseases, such as Pearson syndrome, a fatal pediatric disease, and hematological disorders that include mitochondrial dysfunction.

Findings on safety and efficacy of MAT, both pre–clinical and clinical, may be found in these publications:

https://www.nature.com/articles/s41536–021–00167–7

https://www.science.org/doi/10.1126/scitranslmed.abo3724

Minovia was founded by leading researchers in mitochondrial biology and is headquartered in Haifa, Israel, with operations in Massachusetts.

For more information, visit http://minoviatx.com/.

Contact Information

Shai Melcer, CBO

3 HaSadna st., Tirat Carmel

Israel

Shai.melcer@minoviatx.com

+972–747033354


GLOBENEWSWIRE (Distribution ID 8722760)

]]>
Quantexa Positioned by Global Risk Analyst Firm Chartis as a Category Leader in 2023 RiskTech 100 Report for Trade-Based Money Laundering Solutions http://www.kuwaitfinancialexpress.com/quantexa-positioned-by-global-risk-analyst-firm-chartis-as-a-category-leader-in-2023-risktech-100-report-for-trade-based-money-laundering-solutions/ Thu, 22 Dec 2022 13:00:00 +0000 http://www.kuwaitfinancialexpress.com/?p=306592 LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) — Today Quantexa, a global leader in Decision Intelligence (DI) solutions for the public and private sectors, announced that their Decision Intelligence Platform has been recognized as a category leader in the Chartis RiskTech100 report for Trade–Based Anti–Money Laundering Solutions (TBAML). Quantexa's Decision Intelligence Platform has also been recognized by Chartis as a category leader in the recently released Chartis Financial Crime Risk Management Systems, Entity Management and Analytics Quadrant report.

RiskTech 100: Trade–Based Anti–Money Laundering Solutions
The 2023 RiskTech100 report ranks the world's major players in risk and compliance technology. In the Trade–based money laundering (TBML) category Quantexa was named as a category leader for data support of their enterprise solution. The Quantexa Trade AML Solution was also ranked for depth of typology coverage, breadth of analytical techniques and workflow.

Today's Anti–money laundering efforts face many growing and unresolved challenges. In a digital and globalized world, criminals are using a wide range of strategies to be successful "" making context a critical factor in the ability to accurately detect trade–based money laundering. By unifying internal and external data sources and scaling to understand billions of transactions, Quantexa's Decision Intelligence Platform helps organizations create a holistic view of transactional, customer, and counterparty information. Quantexa's approach to TBAML provides more accurate and efficient detection so organizations can reduce risk, assure compliance, and protect their reputation. Increased alert quality and automation, combined with reducing the volume of false positives helps organizations gain efficiencies and do more with the resources they already have.

Financial Crime Risk Management Systems: Entity Resolution
Quantexa's dynamic Entity Resolution Solution capability that is a critical part of its industry leading Decision Intelligence Platform was recognized for coverage, scalability, data enrichment, depth and breadth of data sources supported.

Quantexa's Entity Resolution Solution is an advanced data matching capability that connects disparate and ambiguous internal and external data at scale. Entity Resolution creates focused and complete views of people, organizations, places, and other data delivering game changing data quality and match rate accuracy. Quantexa also supports "dynamic entity resolution', which gives unique flexibility across multiple use cases and informs granular and extensive security protocols.

Decision Intelligence Platform
Quantexa's Decision Intelligence Platform gives enterprises the ability to unify their data by connecting siloed sources and systems, providing the context needed to visualize the complex relationships that enable previously hidden risk to be discovered. Quantexa's unique entity resolution technology can connect the most disparate and ambiguous internal and external data at scale to create single, complete views of people, organizations, places, and other data with 99% accuracy, handling poor quality data with exceptional performance. The result is a single view of data that becomes their most trusted and reusable resource across the organization.

Chartis Chief Researcher Sidhartha Dash said:

"Quantexa's increasingly mature solutions and their strong implementations in large financial institutions leveraging network–based concepts, drove their rise in the RiskTech 100 as well as their leadership in TBAML and Entity Management quadrants."

Quantexa Chief Product Officer Dan Higgins added:

"Quantexa is delighted to be included in the RiskTech 100 report, positioned very strongly amongst an esteemed list of enterprise solution providers. At Quantexa, we are keenly aware that criminals are hiding in plain sight and that traditional monitoring systems and manual controls just can't handle today's complexity, scale of activity and the underlying regulatory shifts, in particular the focus on counterparty risk, as well as customers. The usage of contextual monitoring to detect and manage the holistic financial crime and fraud risks within International Trade, including the identification of prerequisites such as underlying collusion, the presence of shell companies and professional money laundering gatekeeps and enablers has been a defining factor in Quantexa's success in this space."

ABOUT QUANTEXA

Quantexa is a global data and analytics software company pioneering Contextual Decision Intelligence that empowers organizations to make trusted operational decisions by making data meaningful. Using the latest advancements in big data and AI, Quantexa's platform uncovers hidden risk and new opportunities by providing a contextual, connected view of internal and external data in a single place. It solves major challenges across data management, KYC, customer intelligence, financial crime, risk, fraud, and security, throughout the customer lifecycle.

The Quantexa Decision Intelligence Platform enhances operational performance with over 90% more accuracy and 60 times faster analytical model resolution than traditional approaches. Founded in 2016, Quantexa now has more than 500 employees and thousands of users working with billions of transactions and data points across the world. The company has offices in London, New York, Boston, Washington DC, Brussels, Toronto, Singapore, Melbourne, and Sydney. For more information, contact Quantexa here or follow us on LinkedIn.

ABOUT CHARTIS

Chartis is a research and advisory firm that provides technology and business advice to the global risk management industry. Chartis provides independent market intelligence regarding market dynamics, regulatory trends, technology trends, best practices, competitive landscapes, market sizes, expenditure priorities, and mergers and acquisitions. Chartis' RiskTech Quadrant reports are written by experienced analysts with hands–on experience of selecting, developing, and implementing risk management systems for a variety of international companies in a range of industries, including banking, insurance, capital markets, energy, and the public sector.

Media Inquiries:

C: Laurel Case, VP, Fight or Flight

T: +1 315 663 6780

E: Quantexa@fightflight.co.uk

C: Adam Jaffe, SVP of Corporate Marketing
T: +1 609 502 6889
E: adamjaffe@quantexa.com
"" or ""
RapidResponse@quantexa.com


GLOBENEWSWIRE (Distribution ID 1000773686)

]]>
Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases http://www.kuwaitfinancialexpress.com/minovia-therapeutics-reports-first-clinical-data-demonstrating-disease-modifying-efficacy-and-safety-of-mitochondrial-augmentation-therapy-in-pediatric-patients-with-primary-mitochondrial-diseases/ Wed, 21 Dec 2022 19:00:00 +0000 http://www.kuwaitfinancialexpress.com/?p=306589 First in human clinical study provides proof–of–concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of large–scale mitochondrial DNA (mtDNA) deletion syndromes

Study showed improved quality of life measures in children with Pearson Syndrome and Kearns–Sayre Syndrome spectrum

No treatment–related adverse effects reported in study

WOBURN, Mass. and HAIFA, Israel, Dec. 21, 2022 (GLOBE NEWSWIRE) — Minovia Therapeutics, a clinical–stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine. The study was conducted in collaboration with global leaders in the field of hematology and primary mitochondrial disease at Sheba Medical Center (Tel Hashomer, Israel).

Single, large deletions in mitochondrial DNA (mtDNA) can lead to a variety of devastating diseases, including Pearson Syndrome and Kearns–Sayre Syndrome (KSS). These mtDNA deletion syndromes are sporadic, uncurable and ultimately fatal. Pearson syndrome is a bone marrow failure disease that usually begins in infancy. In addition to presenting with sideroblastic anemia, patients are characterized by exocrine pancreas dysfunction. About half of patients die in infancy or childhood, while many who survive go on to develop KSS, a progressive multisystem disorder.

"These findings demonstrate that mitochondrial augmentation therapy is feasible in children with mitochondrial DNA deletion syndromes and that autologous CD34+ cells augmented with mitochondria derived from maternal blood may potentially deliver some functional improvement for patients living with these debilitating diseases for which there are no available therapies," said Elad Jacoby, M.D., Ph.D., Hemato–oncology Pediatric department, Sheba Medical Center.

MAT is designed to rescue mitochondrial function and metabolic activity in diseased cells through enrichment with healthy mitochondria. This builds upon Minovia's previous demonstration that MAT provides long–term functional benefit in an immunocompromised mouse model, and that mitochondria can transfer between hematopoietic stem cells (HSCs) in vivo (Jacoby et al 2021). Preclinical studies showed that hematopoietic stem and progenitor cells (HSPCs) can transfer normal mitochondria to hematopoietic and non–hematopoietic cells and improve disease features (Rocca et al., 2017).

Minovia is developing MAT to treat Primary Mitochondrial Diseases such as Pearson syndrome, as well as other mitochondrially–related sideroblastic anemias. The Company's lead investigational candidate, MNV–101 (MNV–BM–BLD), has been granted the Fast–Track, Orphan Drug and Rare Pediatric Disease designations by the U.S. Food and Drug Administration.

The latest study reported results from six patients ranging from 2 to 7 years of age: four with Pearson syndrome and two with KSS spectrum. All six patients suffered from significant failure to thrive and advanced multi–organ disease, which was either immediately or potentially life–threatening, requiring multiple ongoing supportive care interventions.

Key Findings

  • No treatment–related adverse events were reported. Adverse events related to the leukapheresis procedure were managed with standard medical care. Adverse events that occurred following treatment were expected due to the patient's underlying disease and resolved spontaneously or with appropriate treatment.
  • Higher levels of normal mitochondrial DNA were observed in the blood of four out of six patients, indicating a reduction of mitochondria with large DNA deletions.
  • Clinical improvement in aerobic function was observed in some patients, and five of six patients experienced weight gain.
  • Quality of life measurements showed improvement in most patients. Changes in the general well–being of children and physical activity were reported, along with increased time spent awake and in play.
  • A series of aerobic and endurance tests were performed on two patients. Both patients demonstrated improvement in leg muscle strength and endurance at 6 and 12 months post treatment.
  • One patient, who at baseline was unable to walk any distance, was able to walk 10 meters at 12 months and had improvement on the 30–second sit–to–stand test.
  • Another patient demonstrated improvement in muscle function in some tests and a sustained improvement in others, including the six–minute walk test and sit–to–stand capacity at 6 and 12 months.

"We are tremendously encouraged by evidence of improvement to the quality of life and well–being of the children treated with MAT, including clinical improvements in aerobic function, weight gain and increased strength and endurance,” said Natalie Yivgi Ohana, Ph.D., co–founder and CEO of Minovia. “We believe these findings lay important groundwork for further development of MAT and future clinical trials to demonstrate the effectiveness and safety of MAT in patients with primary mitochondrial disorders and other diseases. Our excellent collaboration with the clinicians and teams at the Sheba Medical Center, as well as with patient advocacy groups, will enable us to accelerate the clinical development plans for Pearson Syndrome patients.”

About Primary Mitochondrial Diseases (PMD) and Mitochondrial Dysfunction
Primary Mitochondrial Diseases (PMDs) are chronic, genetic disorders that occur when mitochondria fail to produce enough energy for the body to function properly. Mitochondrial diseases affect about one in 5,000 people globally and can be sporadic or inherited and onset can occur at any age. Mitochondrial diseases can affect almost any part of the body, including the cells of the brain, nerves, muscles, kidneys, heart, liver, eyes, ears or pancreas. Mitochondrial dysfunction also plays an important role in more prevalent diseases, such as Alzheimer's disease, muscular dystrophy, amyotrophic lateral sclerosis and diabetes.

About Minovia
Minovia Therapeutics is a clinical–stage global biotechnology company committed to the discovery and development of novel approaches to treating diseases caused by mitochondrial dysfunction. Minovia's Mitochondrial Augmentation Therapy (MAT) platform is designed to extend and enhance human lives by restoring mitochondrial function using autologous stem cells enriched with healthy, functional mitochondria. This unique approach capitalizes on the natural ability of mitochondria to transfer between cells. The company's initial clinical focus is on primary mitochondrial diseases, such as Pearson syndrome, a fatal pediatric disease, and hematological disorders that include mitochondrial dysfunction. Minovia was founded by leading researchers in mitochondrial biology and is headquartered in Haifa, Israel, with operations in Massachusetts. For more information, visit http://minoviatx.com/.


GLOBENEWSWIRE (Distribution ID 8718621)

]]>